Medline Recalls Angiographic Syringes After FDA Warning Over Life-Threatening Disconnection Risk
核心洞察
Medline is recalling Namic angiographic rotating adaptor control syringes (搜索) due to devices becoming loose or disconnected during use, potentially causing air embolisms and biohazard exposure.
The FDA issued a warning letter after finding that Medline did not take adequate action despite receiving 250 complaints and reports of four serious injuries between June 2023 and February 2024.
Manufacturing issues including excess silicone contamination and inadequate cleanroom maintenance at Medline's Glen Falls facility contributed to the device failures.
Medline Industries has initiated a recall of its Namic angiographic rotating adaptor control syringes (搜索) following serious safety concerns that led to a FDA warning letter, highlighting critical manufacturing defects that pose life-threatening risks to patients undergoing medical imaging procedures.
The Northfield, Illinois-based medical device manufacturer began the recall in February after reports that the syringes may unwind during use, potentially causing biohazard exposure for clinicians and blood loss and infection (搜索) for patients. Most critically, the device failures can introduce air into the line, leading to air embolism (搜索)—a life-threatening condition where air bubbles block blood flow.
Safety Profile and Reported Incidents
As of March 13, Medline had documented four serious injuries and no deaths associated with the syringe disconnection issue, according to the FDA recall notice. The company received 250 complaints related to the problem between June 2023 and February 19, 2024, demonstrating the widespread nature of the manufacturing defect.
The Namic angiographic rotating adaptor control syringes (搜索) are specifically designed to administer radiographic contrast media during medical imaging procedures. When these devices fail, the consequences extend beyond equipment malfunction to include direct patient harm and occupational safety risks for healthcare workers.
Manufacturing Root Cause and FDA Investigation
The FDA's December inspection of Medline's Glen Falls, New York facility, where the Namic product line is manufactured, revealed significant quality control failures. Investigators found that Medline did not take actions commensurate with the risk posed by the syringe problems.
The company attributed the disconnection issues to excess silicone contamination in the manufacturing process. In June 2023, Medline had initiated a corrective action plan after receiving initial reports of syringe-to-manifold disconnections, including incidents involving air injection into patients and biohazard exposure for clinicians.
Despite these early warning signs, Medline initially classified the health risk as low. Following the FDA inspection findings in January, the company finally responded by scrapping affected inventory and increasing cleaning frequency of manufacturing equipment to prevent excess silicone buildup.
Regulatory Response and Compliance Issues
The FDA warning letter highlighted Medline's inadequate response to known safety risks. Initially, the company proposed issuing a field notice rather than conducting a full product removal, citing "the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage."
Only after multiple discussions with the FDA about recall strategy did Medline develop a revised plan for complete product removal one month later. The regulatory action underscores the agency's expectation that manufacturers respond proportionally to identified safety risks.
Cleanroom Manufacturing Deficiencies
Beyond the silicone contamination issue, FDA investigators documented broader manufacturing quality problems at the Glen Falls facility. Accumulated particulates were observed on top of manufacturing machines in cleanrooms, with the last documented cleaning occurring on November 26, 2023.
Significantly, Medline had received 114 complaints of foreign matter or hair contamination since that cleaning date, yet the company failed to assess the field impact and inventory for products manufactured in those compromised cleanrooms.
Emergency Use Protocols
In recognition of the critical nature of angiographic procedures, the FDA has established limited emergency use protocols for the recalled devices. In rare cases where angiography is urgently required and no alternative device is available, clinicians may use the Namic rotating adaptor syringe "with extreme caution and vigilance."
Healthcare providers utilizing the device under these emergency circumstances must manually stabilize all syringe-to-manifold connections and maintain continuous monitoring throughout the entire procedure. This requirement places additional burden on clinical teams during already complex interventions.
Industry Impact and Patient Safety
Medline sent notification letters to customers on February 27, instructing them to destroy and quarantine all affected devices. The recall represents a significant disruption to angiographic procedures, particularly given Medline's position as a major distributor of medical supplies.
The case illustrates the critical importance of robust manufacturing quality systems in medical device production, where component failures can directly translate to patient harm. The progression from initial complaints to formal recall also demonstrates the regulatory framework's role in ensuring appropriate manufacturer response to safety signals.